Back to Evidence

Adult CAP: Auditing Severity, Antibiotic Coverage and Duration | QSevidence 2026

Evidence-Based Medicine18 min read

Adult community-acquired pneumonia requires three distinct decisions: where care should occur, which organisms need initial coverage, and when treatment should be reassessed. Prognostic scores, resistance evidence and recovery trajectories inform different parts of that process.

Adult CAP: Auditing Severity, Antibiotic Coverage and Duration | QSevidence 2026

QSevidence can provide an entry point for finding and organizing information as an AI-powered medical reference. This article develops a traceable review method for clinical discussion. It does not provide an individual prescription or claim that the information tool is a validated pneumonia decision system.

What the underlying work can establish

The research plan groups adult CAP care into risk assessment, initial empirical treatment and duration optimization. It proposes examining PSI, CURB-65 and SMART-COP, considering PCT and CRP, and comparing outpatient, ward and critical-care settings against local resistance information. These are useful review questions rather than interchangeable prediction tasks.

The supplied results are a narrative discussion. They contain no reproducible search history, screening record, risk-of-bias assessment or patient-level dataset. They therefore do not establish a completed systematic review, meta-analysis or new treatment effect. Unverified numerical claims about unidentified pathogens or days saved have not been reproduced as study findings.

Separate the three decision axes

A practical audit distinguishes present illness severity, the probability of particular pathogens, and response after effective treatment begins. Severe illness warrants appropriate monitoring and support, but does not independently establish MRSA or Pseudomonas infection. Improvement likewise does not prove that every component of the initial broad regimen was necessary.

Document three separate explanations: why this care setting was selected, what supports the coverage being used, and what new information could change the plan. This structure exposes reasoning gaps that disappear when all three decisions are compressed into a single high-risk label.

Match the score to its intended question

PSI and CURB-65 support prognosis and hospitalization assessment; neither identifies a causative organism. The 2019 ATS/IDSA guideline favors PSI alongside clinical judgment for hospitalization decisions. Critical-care assessment additionally requires attention to organ-support needs and severe-CAP criteria. SMART-COP addresses intensive respiratory or vasopressor support rather than simply duplicating mortality prediction.

For older adults or people with comorbidities, record baseline cognition, oxygen use, oral intake and practical support. A correctly calculated score does not make the clinical picture complete, and an initial low-risk category cannot overrule subsequent deterioration. Urgent respiratory or circulatory instability requires timely clinical assessment, not completion of an online search.

Diagnosis also requires more than fever and an inflammatory-marker result. Symptoms, examination, imaging and alternative explanations belong together. For evidence review, preserve the test method, collection time and diagnostic question; uncertainty after a negative investigation should remain visible rather than being converted into an automated exclusion.

Audit standard treatment and additional resistance coverage separately

Empirical therapy is a decision under uncertainty, not a competition for the broadest spectrum. In the 2019 outpatient framework, adults without relevant comorbidities are distinct from those with comorbidities or requiring hospitalization. Amoxicillin or doxycycline may be considered in the former setting; macrolide monotherapy carries the condition of local pneumococcal resistance below 25%. A respiratory fluoroquinolone is not the default for every otherwise healthy outpatient.

In severe CAP, choosing standard combination treatment is separate from adding MRSA or antipseudomonal coverage. Review prior respiratory isolates, recent hospitalization with parenteral antibiotics, the nature of structural lung disease and locally validated risks in context. Neither an ICU bed nor an undifferentiated COPD label is an unconditional broad-coverage switch.

The IDSA clinical pathway separates severity and resistance branches and emphasizes local susceptibility information. Its practice enhancements should be distinguished from formal guideline recommendations. Allergy phenotype, organ function, interacting medicines and local availability still require professional review; doses are intentionally omitted here.

Make reassessment capable of changing the plan

Record what each microbiological test is intended to change. Preserve specimen quality and its timing relative to antibiotic exposure. Positive results require interpretation of colonization versus infection; negative results require attention to test performance and context. Neither direction automatically settles the entire diagnosis.

PCT and CRP are supporting information. The 2019 guideline does not endorse withholding necessary initial antibacterial treatment for confirmed CAP solely because PCT is low. Subsequent trends may inform reassessment, but are not universal stop rules. A positive viral result also calls for contextual assessment of bacterial coinfection rather than a blanket rule.

When recovery is unsatisfactory, revisit diagnosis, drug activity, complications and alternative causes instead of treating extension as the only option. When narrowing is chosen, document the new supporting evidence and observation plan. When broader treatment continues, identify the unresolved concern. This is a proposed review method, not a proven mortality-reduction intervention.

Read duration recommendations with their version and conditions

The narrative repeatedly contrasts 5–7 days with 10–14 days. That is not a complete account of current guidance. The 2025 ATS update conditionally supports less than 5 days, with a minimum of 3, for stable adult outpatients and stable nonsevere inpatients. Stable severe inpatients should receive at least 5 days. The shorter-course recommendation has low-quality evidence and requires individualization, not automatic stopping on day three.

Stability is an overall clinical assessment, not one normal temperature or laboratory result. Complications, particular pathogens and other complex features can limit application of shorter-course evidence. Guidance principally addressing immunocompetent adults should not be transferred uncritically to immunocompromised patients. Document the effective treatment already received and the follow-up conditions. Discharge, oral conversion and antibiotic completion are separate decisions.

A prospective research and quality-improvement agenda

A future study could define documented coverage justification, changes after reassessment and duration after stability as separate variables. Capture severity, organ function, previous resistant isolates, diagnostic availability, effective-treatment timing, complications and follow-up completeness. Avoid collapsing them into a generic risk category.

Evaluate recovery, repeat visits, readmissions, adverse events and exposure together. Fewer treatment days alone do not establish success. Selection, missing tests and longer treatment driven by severe disease can confound observational comparisons. External validation and explicit human responsibility should precede automated recommendations. No sample size, ethics approval or completed model performance is claimed here.

Frequently asked questions

How can QSevidence help organize a CAP review?

It can support searches organized by care setting, coverage and duration, retaining original links, dates and applicability conditions. The clinical team remains responsible for applying evidence to the patient; retrieval capability is not clinical validation.

How can clinicians compare guideline versions efficiently?

Fix the population and decision first, then compare recommendation strength, certainty and exceptions. Label the 2019 initial-treatment framework separately from the 2025 focused update instead of extracting a context-free duration number.

How can review findings support follow-up?

The care team can specify symptoms to monitor, contact routes, responsibility for pending results and reassessment conditions. Marked breathing difficulty, altered consciousness or rapid deterioration requires timely medical care rather than waiting for an online answer.

Sources and scope

  • 2019 ATS/IDSA executive summary: initial evaluation and treatment framework.
  • IDSA CAP clinical pathway: severity, resistance-risk branches and daily stewardship review; linked above.
  • 2025 ATS focused update: current duration recommendations; linked above. Official indexed recommendation text was checked, but some full-text redirects were unavailable. Complete supplementary-material review is not claimed.

This is educational evidence-review material, not individualized treatment advice or a substitute for local guidance. Unverified numerical effects and product accuracy or outcome claims have been excluded.